Cancer Therapeutics Markets

Table of Contents

1. Overview

• 1.1 Introduction
• 1.2 Goals and Objectives
• 1.3 Study, Scope and Format
• 1.4 Methodology
• 1.5 Summary of Major Findings

2. Introduction to the Cancer Therapeutic Market

3. Cancer Therapeutics Market Overview

• 3.1 Cancer Therapeutics in the Pharmaceutical and Biotech Industry
• 3.2 Business Analysis of the Cancer Market
  • 3.2.1 Growth Potential
  • 3.2.2 Demographics of Cancer
  • 3.2.3 The Global Market for Cancer Therapies
    • 3.2.3.1 European Cancer Market
    • 3.2.3.2 The Environment in the U.K. for Clinical Research into New Anti-Cancer Therapies
    • 3.2.3.3 The Suitability of Current U.K. and E.U. Regulatory Regimes
    • 3.2.3.4 Comments on the Current E.U. Regulatory Environment
• 3.3 The Pharmaceutical Industry
• 3.4 Cancer Therapies
  • 3.4.1 Market Size
• 3.5 New Product Trends
  • 3.5.1 Chemotherapy
  • 3.5.2 Hormone Therapy
  • 3.5.3 Photodynamic Therapy and Photosensitizers
  • 3.5.4 Gene Therapy
    • 3.5.4.1 Tumor-Suppressor Gene Therapy
    • 3.5.4.2 Immunomodulatory Gene Therapy
    • 3.5.4.3 Suicide Gene Therapy
  • 3.5.5 Radiation Therapy
  • 3.5.6 Farnesyl Transferase Inhibitors (FTIs)
  • 3.5.7 Genetic Screening
  • 3.5.8 Biological Therapies
  • 3.5.9 Interferons
  • 3.5.10 Interleukins
  • 3.5.11 Tumor Necrosis Factor (TNF)
  • 3.5.12 Colony-Stimulating Factors (CSFs)
  • 3.5.13 Monoclonal Antibodies (MAbs)
  • 3.5.14 Cancer Vaccines
  • 3.5.15 Anti-Sense Therapy
  • 3.5.16 Adjuvants
  • 3.5.17 Angiogenesis Inhibitors
  • 3.5.18 Hyperthermia
  • 3.5.19 Transplants
    • 3.5.19.1 Bone Marrow Transplants
    • 3.5.19.2 Stem Cell Transplants

4. The Disease of Cancer

• 4.1 Incidence of Cancer
  • 4.1.1 U.S. Statistics
  • 4.1.2 Global Statistics
• 4.2 Causes of Cancer
• 4.3 Risk Factors
  • 4.3.1 Smoking
  • 4.3.2 Diet
  • 4.3.3 Radiation
  • 4.3.4 Occupational Risks
  • 4.3.5 Medicine and Infection
  • 4.3.6 Environmental Pollution
  • 4.3.7 Reproductive Factors
  • 4.3.8 Socio-Economic Factors
• 4.4 Cancer Costs

5. Specific Cancers

• 5.1 Bladder Cancer
  • 5.1.1 Overview of the Disease
  • 5.1.2 Diagnosis and Staging
  • 5.1.3 Therapy
  • 5.1.4 Test for Bladder Cancer Analyzes DNA in Urine
  • 5.1.5 Drugs in Development
• 5.2 Brain Cancer
  • 5.2.1 Overview of the Disease
  • 5.2.2 Treatment Options
• 5.3 Breast Cancer
  • 5.3.1 Overview of the Disease
  • 5.3.2 Therapeutic Drugs
  • 5.3.3 Market Overview for Breast Cancer Therapeutics
• 5.4 Cervical Cancer
  • 5.4.1 Overview of the Disease
  • 5.4.2 Treatment Options
• 5.5 Colon Cancer
  • 5.5.1 Overview of the Disease
  • 5.5.2 Treatment Options
  • 5.5.3 Market Overview for Colon Cancer Therapeutics
• 5.6 Leukemia
  • 5.6.1 Overview of the Disease
  • 5.6.2 Treatment Options
• 5.7 Lymphoma
  • 5.7.1 Overview of the Disease
  • 5.7.2 Treatment Options
• 5.8 Lung Cancer
  • 5.8.1 Overview of the Disease
  • 5.8.2 Treatment Options
  • 5.8.3 Breakthrough Treatments for Lung Cancer
  • 5.8.4 Market Overview for Lung Cancer Therapeutics
• 5.9 Ovarian Cancer
  • 5.9.1 Overview of the Disease
  • 5.9.2 Treatment Options
• 5.10 Prostate Cancer
  • 5.10.1 Overview of the Disease
  • 5.10.2 Treatment Options

6. Corporate Profiles

• 6.1 AstraZeneca Plc
• 6.2 Biogen Idec, Inc.
• 6.3 Bristol-Myers Squibb
• 6.4 Genentech, Inc.
• 6.5 Genta, Inc.
• 6.6 Genzyme Oncology
• 6.7 GlaxoSmithKline Plc
• 6.8 ImClone Systems, Inc.
• 6.9 Medarex
• 6.10 Millennium Pharmaceuticals, Inc.
• 6.11 Novartis AG
• 6.12 Onyx Pharmaceuticals, Inc.
• 6.13 OSI Pharmaceuticals, Inc.
• 6.14 Pfizer
• 6.15 Regeneron Pharmaceuticals, Inc.
• 6.16 Roche
• 6.17 Sanofi-Aventis

7. References

• 7.1 Online References for Cancer
• 7.2 Print Sources
• 7.3 Product Approvals for Cancer Indications

INDEX OF TABLES

• Table 2.1: The 646 Medicines in Development for Cancer, 2006
• Table 2.2: Drug Approvals for Cancer Indications, 1996-2007
• Table 3.1: Opportunities for Molecular-Targeting Therapeutics for Cancer
• Table 3.2: Top U.S. Biotechnology Companies by Market Capitalization
• Table 3.3: Top Pharmaceutical Companies by Market Capitalization
• Table 3.4: Clinical Development for some of Hoffman-La Roche Products
• Table 3.5: Global Pharmaceutical Industry R&D Spending, 1995-2006
• Table 3.6: U.S. Government NIH Research Budget, 1995-2007
• Table 3.7: Health Spending as Percentage of GDP by Country
• Table 3.8: Spending on Health by Country
• Table 3.9: Annual Spending on Cancer Drugs Per Person
• Table 3.10: Patients Per Cancer Specialist
• Table 3.11: World Healthcare Cancer Therapeutics Markets by Region
• Table 3.12: The Projected Growth in the U.S. Market for Cancer Therapeutics, 1998-2006
• Table 3.13: The Projected Growth in the European Market for Cancer Therapeutics, 1998-2006
• Table 3.14: The Projected Growth in the Japanese Market for Cancer Therapeutics, 1998-2006
• Table 3.15: Cancer Vaccines Approved or in Phase III Clinical Trials
• Table 3.16: Anti-Angiogenic Drugs in Clinical Trial for Cancer
• Table 4.1: Estimates of New Cancer Cases and Deaths in the U.S. by Sex for all Cancer Sites, 2007
• Table 4.2: Estimated New Cancer Cases and Deaths for Ten Leading Cancer Sites in the U.S., by Sex, 2007
• Table 4.3: Estimated Worldwide Number of New Cancer Cases and Deaths by Leading Cancer Sites and by Level of Economic Development, 2007
• Table 4.4: Estimated Number of New Cancer Cases and Deaths by World Area, 2007
• Table 4.5: Cancer Death Rates per 100,000 Population (and Rank) for all Cancer Sites by Country, 2006
• Table 4.6: Genes and Cancer Risk
• Table 4.7: Carcinogens in the Workplace
• Table 5.1: Drugs Used in Bladder Cancer Therapy
• Table 5.2: Drugs in Development for Bladder Cancer
• Table 5.3: Medicines in Development for Brain Cancer
• Table 5.4: Classes of Chemotherapy Drugs Used to Treat Breast Cancer
• Table 5.5: U.S. Sales of Doxorubicin, 2001-2009
• Table 5.6: New Therapeutics for Breast Cancer
• Table 5.7: Other Classes of Drugs Used to Treat Breast Cancer
• Table 5.8: Worldwide AstraZeneca' s Nolvadex Sales, 2000-2005
• Table 5.9: Aromatase Inhibitors
• Table 5.10: Worldwide Sales Estimates for Arimidex, 2000-2008
• Table 5.11: Worldwide Herceptin Sales, 1999-2005
• Table 5.12: Innovative Drug Therapies applied to the Breast Cancer Market Sector
• Table 5.13: Treatment Regimens for Advanced Breast Cancer
• Table 5.14: Medicines in Development for Cervical Cancer
• Table 5.15: New Therapies for Colon Cancer
• Table 5.16: Worldwide Sales for Xeloda, 2001-2005
• Table 5.17: Worldwide Sales of Tomudex, 1998-2005
• Table 5.18: Medicines in Development for Leukemia
• Table 5.19: Pricing of Novartis' Gleevec in Various Strengths in the U.S.
• Table 5.20: Medicines in Development for Lymphoma
• Table 5.21: U.S. Sales of Rituxan, 1999-2005
• Table 5.22: Cytotoxics for Lung Cancer Therapy
• Table 5.23: Anti-Angiogenics for Lung Cancer
• Table 5.24: Drugs in Development for Lung Cancer
• Table 5.25: Current Therapies for Ovarian Cancer
• Table 5.26: Emerging Therapies for Ovarian Cancer
• Table 5.27: New Development Therapies for Ovarian Cancer
• Table 5.28: New Drug Types for Ovarian Cancer
• Table 5.29: Medicines in Development for Prostate Cancer
• Table 6.1: Potential Therapeutic Indications and Development Stages
• Table 6.2: Products in Clinical Development in Phase II and III (Including Additional Indications)
• Table 7.1: Drugs Currently Approved for the Treatment of Cancer